目的 研究乳腺癌患者外周血中趋化因子CCL20及其受体CCR6的表达变化在乳腺癌发病机制中的作用.方法 把乳腺癌患者分为2组,癌组织上有CCR6表达的为CCR6+组,癌组织上未见有CCR6表达的为CCR6 -组.采用酶联免疫吸咐试验(ELISA)检测乳腺癌患者及正常人血清中CCL20水平,同时用流式细胞仪分析外周血CD3 +T淋巴细胞表面CCR6的表达.结果 CCR6+组患者血清CCL20水平明显高于正常对照组和CCR6 -组(P均＜0.01),各组外周血CD3+T淋巴细胞表面CCR6的表达差异无统计学意义.结论 CCR6+组患者血清CCL20水平升高可能在部分乳腺癌的发病过程中发挥作用.%Objective To study the role of peripheral blood chemokine CCL20 and its receptor CCR6 in the pathogenesis of breast cancer. Methods The patients with breast cancer were classified into 2 groups, according to the expression of CCR6 in breast cancer tissue. One was with positive CCR6 expression (CCR6 + patients) , and another was without CCR6 expression ( CCR6- patients). The serum levels of CCL20 were determined by enzyme-linked immunosorbent assay ( ELISA) in patients with breast cancer and healthy controls. Meanwhile, the chemokine receptor CCR6 expression on peripheral blood CD3 + T-lymphocytes from patients and controls was analyzed by flow cytometry. Results The serum levels of CCL20 in CCR6 + patients were significantly higher than those in CCR6- patients and controls ( P＜0. 01 ). There was no statistical difference in the expression of CCR6 on peripheral blood CD3 * T-lymphocytes among the 3 groups. Conclusions The increase of CCL20 in CCR6 + patients may play a role in pathogenesis of partial breast cancer.
展开▼
